Construction and immunogenicity of a recombinant pseudorabies virus expressing the G protein of Nipah virus in mice

Abstract

Nipah virus disease, caused by Nipah virus (NiV), is a zoonotic infectious disease with an extremely high fatality rate. Owing to the absence of effective countermeasures, Nipah virus disease has caused substantial economic losses in the swine farming industry. Vaccines represent the most cost-effective approach for prevention and control. Herein, we describe the development of a recombinant pseudorabies virus (PRV)-vectored vaccine (designated PRV-HNX-ΔTK/gE-NiV-G), which expresses the codon-optimized full-length glycoprotein of Nipah virus (NiV-G). The biological characteristics of this strain, including plaque morphology, growth kinetics, and genetic stability, were evaluated in vitro. Furthermore, the recombinant virus exhibited favorable safety profiles in mice. Intramuscular administration of PRV-HNX-ΔTK/gE-NiV-G elicited high-titer neutralizing antibodies against NiV-G and a robust cellular immune response in BALB/c mice. Taken together, these findings indicate that PRV-HNX-ΔTK/gE-NiV-G has potential as a promising candidate for the development of bivalent vaccines that target both NiV and PRV infections.

Keywords

Nipah virus / Glycoprotein / PRV / Recombinant vector vaccine / Immunogenicity

References

[1] Anish TS. Nipah virus is deadly - But smart policy changes can help quell pandemic risk. Nature, 2023, 622(7982): 219

[2] Arunkumar G, Chandni R, Mourya DT, Singh SK, Sadanandan R, Sudan P, Bhargava B. Outbreak investigation of Nipah virus disease in Kerala, India, 2018. The Journal of Infectious Diseases, 2019, 219(121867-1878

[3] Bowden TA, Aricescu AR, Gilbert RJ, Grimes JM, Jones EY, Stuart DI. Structural basis of Nipah and Hendra virus attachment to their cell-surface receptor ephrin-B2. Nature Structural & Molecular Biology, 2008, 15(6): 567-572

[4] Chakraborty S, Deb B, Barbhuiya PA, Uddin A. Analysis of codon usage patterns and influencing factors in Nipah virus. Virus Research, 2019, 263: 129-138

[5] Ching PK, De Los Reyes VC, Sucaldito MN, Tayag E, Columna-Vingno AB, Malbas FFJr., Bolo GCJr., Sejvar JJ, Eagles D, Playford G, et al.. Outbreak of henipavirus infection, Philippines, 2014. Emerging Infectious Diseases, 2015, 21(2): 328-331

[6] Chingtham S, Kulkarni DD, Sivaraman S, Mishra A, Pateriya AK, Singh VP, Raut AA. Novel triplex nucleic acid lateral flow immunoassay for rapid detection of Nipah virus, Middle East respiratory syndrome coronavirus and Reston ebolavirus. Animal Diseases, 2024, 4: 21

[7] Chua KB. Nipah virus outbreak in Malaysia. Journal of Clinical Virology, 2003, 26(3): 265-275

[8] Concordet JP, Haeussler M. CRISPOR: Intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens. Nucleic Acids Research, 2018, 46(W1W242-w245

[9] Deng L, Gu S, Huang Y, Wang Y, Zhao J, Nie M, Xu L, Lai S, Ai Y, Xu Z, et al.. Immunogenic response of recombinant pseudorabies virus carrying B646L and B602L genes of African swine fever virus in mice. Veterinary Microbiology, 2023, 284 109815

[10] Doyle MP, Kose N, Borisevich V, Binshtein E, Amaya M, Nagel M, Annand EJ, Armstrong E, Bombardi R, Dong J, et al.. Cooperativity mediated by rationally selected combinations of human monoclonal antibodies targeting the henipavirus receptor binding protein. Cell Reports, 2021, 36(9 109628

[11] Eaton BT, Broder CC, Middleton D, Wang LF. Hendra and Nipah viruses: Different and dangerous. Nature Reviews Microbiology, 2006, 4(1): 23-35

[12] Edwards, S. 2007. OIE standards for vaccines and future trends. Revue Scientifique Et Technique 26 (2): 373–378. https://doi.org/10.20506/rst.26.2.1749

[13] Fukushi S, Watanabe R, Taguchi F. Pseudotyped vesicular stomatitis virus for analysis of virus entry mediated by SARS coronavirus spike proteins. Methods in Molecular Biology, 2008, 454: 331-338

[14] Geisbert TW, Bobb K, Borisevich V, Geisbert JB, Agans KN, Cross RW, Prasad AN, Fenton KA, Yu H, Fouts TR, et al.. A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus. Npj Vaccines, 2021, 6(1): 23

[15] Gu Z, Dong J, Wang J, Hou C, Sun H, Yang W, Bai J, Jiang P. A novel inactivated gE/gI deleted pseudorabies virus (PRV) vaccine completely protects pigs from an emerged variant PRV challenge. Virus Research, 2015, 195: 57-63

[16] Gurley, E.S., Hegde, S.T., Hossain, K., Sazzad, H.M.S., Hossain, M.J., Rahman, M., Sharker, M.a.Y., Salje, H., Islam, M.S., Epstein, J.H., et al., 2017. Convergence of humans, bats, trees, and culture in Nipah tirus transmission, Bangladesh. Emerg Infect Dis 23 (9), 1446–1453. https://doi.org/10.3201/eid2309.161922.

[17] Huang H, Xiao S, Qin J, Jiang Y, Yang S, Li T, Gao Y, Li Z, Li T, Su X, et al.. Construction and immunogenicity of a recombinant pseudotype baculovirus expressing the glycoprotein of rabies virus in mice. Archives of Virology, 2011, 156(5753-758

[18] Huang Y, Xu Z, Gu S, Nie M, Wang Y, Zhao J, Li F, Deng H, Huang J, Sun X, et al.. The recombinant pseudorabies virus expressing porcine deltacoronavirus spike protein is safe and effective for mice. BMC Veterinary Research, 2022, 18(1): 16

[19] Jin-Shuo Z, Gareth J, Li-Biao Z, Guang-Jian Z, Shu-Yi Z. Recent surveys of bats (Mammalia: Chiroptera) from China II. Pteropodidae. Acta Chiropterologica, 2010, 12(1103-116

[20] Kaku Y, Noguchi A, Marsh GA, Mceachern JA, Okutani A, Hotta K, Bazartseren B, Fukushi S, Broder CC, Yamada A, et al.. A neutralization test for specific detection of Nipah virus antibodies using pseudotyped vesicular stomatitis virus expressing green fluorescent protein. Journal of Virological Methods, 2009, 160(1–2): 7-13

[21] Kalodimou G, Veit S, Jany S, Kalinke U, Broder CC, Sutter G, Volz A. A soluble version of Nipah virus G=glycoprotein G delivered by vaccinia virus MVA activates specific CD8 and CD4 T cells in mice. Viruses, 2019

[22] Lu M, Yao Y, Zhang X, Liu H, Gao G, Peng Y, Chen M, Zhao J, Zhang X, Yin C, et al.. Both chimpanzee adenovirus-vectored and DNA vaccines induced long-term immunity against Nipah virus infection. Npj Vaccines, 2023, 8(1): 170

[23] Mccann N, O'connor D, Lambe T, Pollard AJ. Viral vector vaccines. Current Opinion in Immunology, 2022, 77 102210

[24] Mclean RK, Graham SP. Vaccine development for Nipah virus infection in pigs. Frontiers in Veterinary Science, 2019, 6: 16

[25] Negrete OA, Wolf MC, Aguilar HC, Enterlein S, Wang W, Mühlberger E, Su SV, Bertolotti-Ciarlet A, Flick R, Lee B. Two key residues in ephrinB3 are critical for its use as an alternative receptor for Nipah virus. PLoS Pathogens, 2006, 2(2 e7

[26] Pernet O, Schneider BS, Beaty SM, Lebreton M, Yun TE, Park A, Zachariah TT, Bowden TA, Hitchens P, Ramirez CM, et al.. Evidence for henipavirus spillover into human populations in Africa. Nature Communications, 2014, 5: 5342

[27] Pigeaud DD, Geisbert TW, Woolsey C. Animal models for Henipavirus research. Viruses, 2023, 15(10 1980

[28] Sarji SA, Abdullah BJ, Goh KJ, Tan CT, Wong KT. MR imaging features of Nipah encephalitis. American Journal of Roentgenology, 2000, 175(2437-442

[29] Sun YY, Liu KS, Zhang C, Ni Z, Zhu YC, Bao HL, Chen L, Ye WC, Hua JG, Huo SX, et al.. Recombinant pseudorabies virus (PRV) expressing stabilized E2 of classical swine fever virus (CSFV) protects against both PRV and CSFV. Antiviral Research, 2023, 211 105548

[30] Wang Z, Amaya M, Addetia A, Dang HV, Reggiano G, Yan L, Hickey AC, Dimaio F, Broder CC, Veesler D. Architecture and antigenicity of the Nipah virus attachment glycoprotein. Science, 2022, 375(65871373-1378

[31] Wang S, Han L, Yu J, Ye G, Liu H, Liu Y, Zhou Q, Zhang Z, Weng C. Construction of two recombinant pseudorabies viruses with deletion of virulence genes and evaluation of their immune protection in mice and piglets. Vaccines, 2025, 13(4): 359

[32] Wei J, Liu C, He X, Abbas B, Chen Q, Li Z, Feng Z. Generation and characterization of recombinant pseudorabies virus delivering African Swine Fever Virus CD2v and p54. International Journal of Molecular Sciences, 2024, 25(1335

[33] Who, 2019. Nipah research and development (R&D) roadmap [Online]. Available: https://www.who.int/publications/m/item/nipah-research-anddevelopment-(r-d)-roadmap (accessed February 7, 2025) [Accessed].

[34] Wu X, Wu H, Wang H, Luo L, Wang J, Wu B, He Q, Cao G, Lei Y, Chen X, et al.. A new strategy to develop pseudorabies virus-based bivalent vaccine with high immunogenicity of porcine circovirus type 2. Veterinary Microbiology, 2021, 255 109022

[35] Xu K, Rajashankar KR, Chan YP, Himanen JP, Broder CC, Nikolov DB. Host cell recognition by the henipaviruses: Crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105(299953-9958

[36] Xu RQ, Wang LQ, Zheng HH, Tian RB, Zheng LL, Ma SJ, Chen HY. Characterization of a gE/gI/TK gene-deleted pseudorabies virus variant expressing the Cap protein of porcine circovirus type 2d. Comparative Immunology, Microbiology and Infectious Diseases, 2023, 101 102054

[37] Yang Y, Xu Z, Tao Q, Xu L, Gu S, Huang Y, Liu Z, Zhang Y, Wen J, Lai S, et al.. Construction of recombinant pseudorabies virus expressing PCV2 Cap, PCV3 Cap, and IL-4: Investigation of their biological characteristics and immunogenicity. Frontiers in Immunology, 2024, 15: 1339387

[38] Yao, L., Hu, Q., Chen, S., Zhou, T., Yu, X., Ma, H., A, H.G., Wu, H., Sun, Q., Fan, S., et al., 2021. Recombinant pseudorabies virus with TK/gE gene deletion and Flt3L coexpression enhances the innate and adaptive immune response by activating dendritic cells. Viruses 13 (4). https://doi.org/10.3390/v13040691.

[39] Zhao J, Zhu L, Xu L, Li F, Deng H, Huang Y, Gu S, Sun X, Zhou Y, Xu Z. The construction and immunogenicity analyses of recombinant pseudorabies virus with NADC30-like porcine reproductive and respiratory syndrome virus-like particles coexpression. Frontiers in Microbiology, 2022, 13 846079

[40] Zhou M, Abid M, Cao S, Zhu S. Recombinant pseudorabies virus usage in vaccine development against swine infectious disease. Viruses, 2023

[41] Zhou, J., H. Zhang, K. Zhong, L. Tao, Y. Lin, G. Xie, Y. Tan, Y. Wu, Y. Lu, Z. Chen, et al. 2024. N6-methyladenosine facilitates mitochondrial fusion of colorectal cancer cells via induction of GSH synthesis and stabilization of OPA1 mRNA. National Science Review 11 (3) : nwae039. https://doi.org/10.1093/nsr/nwae039.

Funding

National Natural Science Foundation of China(32373026)

the Independent Science and Technology Innovation Foundation of Huazhong Agricultural University(2662025DKPY007)

the Fundamental Research Funds for the central Universities(266023DKPY004)

RIGHTS & PERMISSIONS

The Author(s)